clinical trial · NCT07332338
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
StemCyte, Inc.·—·available
Post-COVID-19 ConditionPost-COVID ConditionPost-COVID SyndromeLong COVIDChronic FatigueChronic Fatigue SymptomsFatigue Post ViralREGENECYTE®
brief summary
REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.
started
—
primary completion
—
completion
—
last updated
Mar 23, 2026
detailed description
A total of 30 subjects with post-COVID will be enrolled.
official title
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol